---
schema_version: "secwatch.filing_event.v1"
accession: "0001790340-26-000006"
form_type: "8-K"
ticker: "IMRX"
cik: "0001790340"
company_name: "Immuneering Corp"
filed_at: "2026-01-07T23:59:59+00:00"
generated_at: "2026-05-16T11:23:42.157046+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Immuneering reports 64% OS at 12 months in Phase 2a pancreatic cancer trial; median OS not reached

## Summary
- 64% OS at 12 months (SOC 35%) in 34 first-line pancreatic cancer patients at 320 mg atebimetinib + mGnP; median OS not reached.
- Median PFS 8.5 months; 94% OS at 6 months (SOC 67%) and 83% at 9 months (SOC ~47% estimated).
- Grade ≥3 TEAEs in ≥10%: anemia (18%) and neutropenia (18%); no Grade 5 events, no new safety signals.
- Near-term milestones: Phase 3 enrollment start mid-2026; >50 patient data in H1 2026; NSCLC trial start H2 2026.

## SEC filing metadata
- accession: 0001790340-26-000006
- form_type: 8-K
- ticker: IMRX
- cik: 0001790340
- company_name: Immuneering Corp
- filed_at: 2026-01-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1790340/000179034026000006/0001790340-26-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1790340/000179034026000006/imrx-20260107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001790340-26-000006
- JSON: https://secwatch.observer/filing/0001790340-26-000006.json
- Plain text: https://secwatch.observer/filing/0001790340-26-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.